402 related articles for article (PubMed ID: 32859605)
1. Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
Shen YA; Hong J; Asaka R; Asaka S; Hsu FC; Suryo Rahmanto Y; Jung JG; Chen YW; Yen TT; Tomaszewski A; Zhang C; Attarwala N; DeMarzo AM; Davidson B; Chuang CM; Chen X; Gaillard S; Le A; Shih IM; Wang TL
Cancer Res; 2020 Oct; 80(20):4514-4526. PubMed ID: 32859605
[TBL] [Abstract][Full Text] [Related]
2. Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers.
Okazaki A; Gameiro PA; Christodoulou D; Laviollette L; Schneider M; Chaves F; Stemmer-Rachamimov A; Yazinski SA; Lee R; Stephanopoulos G; Zou L; Iliopoulos O
J Clin Invest; 2017 May; 127(5):1631-1645. PubMed ID: 28346230
[TBL] [Abstract][Full Text] [Related]
3. GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy.
Mukha A; Kahya U; Linge A; Chen O; Löck S; Lukiyanchuk V; Richter S; Alves TC; Peitzsch M; Telychko V; Skvortsov S; Negro G; Aschenbrenner B; Skvortsova II; Mirtschink P; Lohaus F; Hölscher T; Neubauer H; Rivandi M; Labitzky V; Lange T; Franken A; Behrens B; Stoecklein NH; Toma M; Sommer U; Zschaeck S; Rehm M; Eisenhofer G; Schwager C; Abdollahi A; Groeben C; Kunz-Schughart LA; Baretton GB; Baumann M; Krause M; Peitzsch C; Dubrovska A
Theranostics; 2021; 11(16):7844-7868. PubMed ID: 34335968
[TBL] [Abstract][Full Text] [Related]
4. Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice.
Boysen G; Jamshidi-Parsian A; Davis MA; Siegel ER; Simecka CM; Kore RA; Dings RPM; Griffin RJ
Int J Radiat Biol; 2019 Apr; 95(4):436-442. PubMed ID: 30557074
[TBL] [Abstract][Full Text] [Related]
5. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
6. Mucin 5AC Serves as the Nexus for β-Catenin/c-Myc Interplay to Promote Glutamine Dependency During Pancreatic Cancer Chemoresistance.
Ganguly K; Bhatia R; Rauth S; Kisling A; Atri P; Thompson C; Vengoji R; Ram Krishn S; Shinde D; Thomas V; Kaur S; Mallya K; Cox JL; Kumar S; Batra SK
Gastroenterology; 2022 Jan; 162(1):253-268.e13. PubMed ID: 34534538
[TBL] [Abstract][Full Text] [Related]
7. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
8. The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
Emberley E; Pan A; Chen J; Dang R; Gross M; Huang T; Li W; MacKinnon A; Singh D; Sotirovska N; Steggerda SM; Wang T; Parlati F
PLoS One; 2021; 16(11):e0259241. PubMed ID: 34731180
[TBL] [Abstract][Full Text] [Related]
9. MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer.
Yi J; Liu C; Tao Z; Wang M; Jia Y; Sang X; Shen L; Xue Y; Jiang K; Luo F; Liu P; Cheng H
EBioMedicine; 2019 May; 43():225-237. PubMed ID: 30898650
[TBL] [Abstract][Full Text] [Related]
10. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells.
Reis LMD; Adamoski D; Ornitz Oliveira Souza R; Rodrigues Ascenção CF; Sousa de Oliveira KR; Corrêa-da-Silva F; Malta de Sá Patroni F; Meira Dias M; Consonni SR; Mendes de Moraes-Vieira PM; Silber AM; Dias SMG
J Biol Chem; 2019 Jun; 294(24):9342-9357. PubMed ID: 31040181
[TBL] [Abstract][Full Text] [Related]
12. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P
Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307
[TBL] [Abstract][Full Text] [Related]
13. c-Myc Overexpression Promotes Oral Cancer Cell Proliferation and Migration by Enhancing Glutaminase and Glutamine Synthetase Activity.
Wang T; Cai B; Ding M; Su Z; Liu Y; Shen L
Am J Med Sci; 2019 Sep; 358(3):235-242. PubMed ID: 31324362
[TBL] [Abstract][Full Text] [Related]
14. Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy.
Masamha CP; LaFontaine P
J Cell Biochem; 2018 Jul; 119(7):6136-6145. PubMed ID: 29633308
[TBL] [Abstract][Full Text] [Related]
15. A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer.
Wang JJ; Siu MK; Jiang YX; Leung TH; Chan DW; Wang HG; Ngan HY; Chan KK
Biomolecules; 2021 Nov; 11(12):. PubMed ID: 34944392
[TBL] [Abstract][Full Text] [Related]
16. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
Liu G; Yang D; Rupaimoole R; Pecot CV; Sun Y; Mangala LS; Li X; Ji P; Cogdell D; Hu L; Wang Y; Rodriguez-Aguayo C; Lopez-Berestein G; Shmulevich I; De Cecco L; Chen K; Mezzanzanica D; Xue F; Sood AK; Zhang W
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25995442
[TBL] [Abstract][Full Text] [Related]
17. Blockage of glutaminolysis enhances the sensitivity of ovarian cancer cells to PI3K/mTOR inhibition involvement of STAT3 signaling.
Guo L; Zhou B; Liu Z; Xu Y; Lu H; Xia M; Guo E; Shan W; Chen G; Wang C
Tumour Biol; 2016 Aug; 37(8):11007-15. PubMed ID: 26894601
[TBL] [Abstract][Full Text] [Related]
18. Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.
Wang D; Wang M; Jiang N; Zhang Y; Bian X; Wang X; Roberts TM; Zhao JJ; Liu P; Cheng H
Oncotarget; 2016 Mar; 7(11):13153-66. PubMed ID: 26909613
[TBL] [Abstract][Full Text] [Related]
19. Brain Tumor Stem Cell Dependence on Glutaminase Reveals a Metabolic Vulnerability through the Amino Acid Deprivation Response Pathway.
Restall IJ; Cseh O; Richards LM; Pugh TJ; Luchman HA; Weiss S
Cancer Res; 2020 Dec; 80(24):5478-5490. PubMed ID: 33106333
[TBL] [Abstract][Full Text] [Related]
20. Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.
Gregory MA; Nemkov T; Reisz JA; Zaberezhnyy V; Hansen KC; D'Alessandro A; DeGregori J
Exp Hematol; 2018 Feb; 58():52-58. PubMed ID: 28947392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
